Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1882 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ARTICLE Table of Contents   
Year : 2000  |  Volume : 11  |  Issue : 3  |  Page : 325-333
Ways of Treating IgA Nephropathies

c/o 81 Gloucester Avenue,Grimsby, England DN 34 5 BU, United Kingdom

Correspondence Address:
E Nigel Wardle
c/o 81 Gloucester Avenue, Grimsby, England DN34 5BU
United Kingdom
Login to access the Email id

PMID: 18209324

Rights and Permissions

Summary: Treatment options for IgA nephropathy (IgAN) must take into consideration the pathophysiology, namely the role of eicosanoids, angiotensin II and monocyte­macrophages releasing reactive oxygen species (ROS). Angiotensin converting enzyme inhibitors and early corticosteroid usage are prime therapies. Tonsillectomy should be considered. Other components of a therapeutic cocktail could be; (a) thromboxane antogonist, (b) leukotriene antagonist, (c) platelet activating factor antagonist, (d) an anti­oxidant and (e) an anti-fibrotic agent like pentoxyfylline. In the new millenium, there will be focus on anti-proliferative measures like platelets dependent growth factor aptamers. For unusual cases with rapid progression, the use of FK-506 or mycophenolate mofetil can be considered.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded514    
    Comments [Add]    

Recommend this journal